The Melanoma Therapeutics Market is expected to register a CAGR of 10.7% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Melanoma Therapeutics Market report covers analysis by Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy); Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generic Drugs), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Melanoma Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Melanoma Therapeutics Market Segmentation
Therapy- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Radiation Therapy
- Opdivo
- Yervoy
- Mekinist+Tafinlar
- Keytruda
- Cotellic
- Zelboraf
- Imlygic
- Generic Drugs
Strategic Insights
Melanoma Therapeutics Market Growth Drivers- Increasing Incidence of Melanoma: The increasing global burden of melanoma, especially with increasing UV irradiation in populations, is major impetus toward melanoma drugs. Increased exposures to the sun, tanning practices, genetic factors, are the reasons the melanoma epidemic continues to evolve. With the higher prevalence of melanomas, there is increasing need for management and treatment methods to control these aggressive skin tumors. This therefore results in rising demand for new therapies in melanoma diseases.
- Advancements in Immunotherapy: The discovery of immunotherapy has become a cutting-edge treatment in melanoma, starting with the introduction of immune checkpoint inhibitors like PD-1 and CTLA-4, which have presented promising results for improvement in patient outcomes. These treatments exploit the body's immune response to attack cancerous cells, and their success in their use has encouraged ongoing research and development of melanoma therapeutics. With continuous research advancing on immunotherapy, the treatments are becoming more targeted and efficient, driving the growth of this market.
- Rising Awareness and Early Detection: As public awareness regarding skin cancer and melanoma grows, it is now moving people to become more proactive in early diagnosis and treatment. In this case, early detection has much to do with the change in prognosis for melanoma since most treatments are effective when the cancer is caught early. Increased awareness and focus on early detection drive the growth of the melanoma therapeutics market because patients are now becoming proactive about seeking treatment once diagnosed.
- Combination Therapies: Combination therapies, where several treatment modalities such as immunotherapy, targeted therapy, and chemotherapy are used together, are increasingly becoming the norm in melanoma treatment. These combination regimens are intended to enhance treatment efficacy by attacking melanoma cells through different mechanisms. The trend toward combination therapies is driving innovation in the development of new treatment protocols and medications that offer better outcomes for patients.
- Personalized Medicine: Targeted therapy: personalization through precise genetic profiles continues to feature strongly in treatment programs for melanomas. Determining specific mutations or molecular profiles characteristic of an individual's melanoma will have therapies designed in conformity with this peculiar characteristic feature, hence augmenting the successful delivery of drugs, as fewer medication side effects become evident; these are reasons behind personalized medicine leading the hot trend of the times of therapeutics to melanoma treatments.
- Accommodate targeted drugs: Targeted therapies, which attack cancer cells directly by targeting them through their respective genetic mutations or molecular markers, have become popular. Therapies that target mutations in BRAF and MEK have been most successful in treating melanoma so far. With the development of targeted therapies being highly effective without many side effects as compared with chemotherapy, increasing adoption is considered one of the significant trends within the melanoma therapeutics market.
- Development of Novel Immunotherapies: One of the promising opportunities in melanoma therapeutics is the development of new immunotherapies. Immunotherapies such as PD-1 inhibitors are promising. However, further research is necessary to develop even more targeted and effective immunotherapies with fewer side effects. Presently, the fields of immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies have been the center of much research activity. The novel therapies developed will be capable of improving patient outcomes and greatly increasing the melanoma therapeutics market.
- Increase in Treatment Accessibility: New, more effective therapies in melanoma include immunotherapies and targeted treatments, whose use should be extended to more patients as these become accessible. Improving coverage for patients, particularly by lowering treatment costs, will facilitate increased accessibility to such advanced treatments in low- and middle-income countries. A significant growth opportunity exists in market access through the extension of cutting-edge melanoma treatments.
- Partnerships and Collaborations for Drug Development: In order to advance new melanoma therapies, there has been a strong emphasis on strategic partnerships among pharmaceutical companies, research institutions, and healthcare providers. These can access sources of funding, technology, and expertise for accelerating drug development and bringing innovative treatments to market more quickly. Companies can also leverage complementary strengths, such as expertise in clinical trials or novel drug delivery methods, to increase the chances of melanoma therapeutics succeeding.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Melanoma Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Melanoma Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Melanoma Therapeutics Market are Increasing Incidence of Melanoma, Advancements in Immunotherapy, and Rising Awareness and Early Detection
The key future trends of the market are Combination Therapies, Personalized Medicine, and Accommodate targeted drugs
The leading players operating in the Melanoma Therapeutics Market include AB Sciences, Amgen, Inc., AstraZeneca, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, F. Hoffman-La Roche Ltd., Merck & Co., Inc., Novartis AG.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Melanoma Therapeutics Market - By Therapy
1.3.2 Melanoma Therapeutics Market - By Drugs
1.3.3 Melanoma Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MELANOMA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MELANOMA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. MELANOMA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. MELANOMA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. MELANOMA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. MELANOMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. IMMUNOTHERAPY
7.4.1. Overview
7.4.2. Immunotherapy Market Forecast and Analysis
7.5. TARGETED THERAPY
7.5.1. Overview
7.5.2. Targeted Therapy Market Forecast and Analysis
7.6. RADIATION THERAPY
7.6.1. Overview
7.6.2. Radiation Therapy Market Forecast and Analysis
8. MELANOMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DRUGS
8.1. OVERVIEW
8.2. DRUGS MARKET FORECASTS AND ANALYSIS
8.3. OPDIVO
8.3.1. Overview
8.3.2. Opdivo Market Forecast and Analysis
8.4. YERVOY
8.4.1. Overview
8.4.2. Yervoy Market Forecast and Analysis
8.5. MEKINIST+TAFINLAR
8.5.1. Overview
8.5.2. Mekinist+Tafinlar Market Forecast and Analysis
8.6. KEYTRUDA
8.6.1. Overview
8.6.2. Keytruda Market Forecast and Analysis
8.7. COTELLIC
8.7.1. Overview
8.7.2. Cotellic Market Forecast and Analysis
8.8. ZELBORAF
8.8.1. Overview
8.8.2. Zelboraf Market Forecast and Analysis
8.9. IMLYGIC
8.9.1. Overview
8.9.2. Imlygic Market Forecast and Analysis
8.10. GENERIC DRUGS
8.10.1. Overview
8.10.2. Generic Drugs Market Forecast and Analysis
9. MELANOMA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Melanoma Therapeutics Market Overview
9.1.2 North America Melanoma Therapeutics Market Forecasts and Analysis
9.1.3 North America Melanoma Therapeutics Market Forecasts and Analysis - By Therapy
9.1.4 North America Melanoma Therapeutics Market Forecasts and Analysis - By Drugs
9.1.5 North America Melanoma Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Melanoma Therapeutics Market
9.1.5.1.1 United States Melanoma Therapeutics Market by Therapy
9.1.5.1.2 United States Melanoma Therapeutics Market by Drugs
9.1.5.2 Canada Melanoma Therapeutics Market
9.1.5.2.1 Canada Melanoma Therapeutics Market by Therapy
9.1.5.2.2 Canada Melanoma Therapeutics Market by Drugs
9.1.5.3 Mexico Melanoma Therapeutics Market
9.1.5.3.1 Mexico Melanoma Therapeutics Market by Therapy
9.1.5.3.2 Mexico Melanoma Therapeutics Market by Drugs
9.2. EUROPE
9.2.1 Europe Melanoma Therapeutics Market Overview
9.2.2 Europe Melanoma Therapeutics Market Forecasts and Analysis
9.2.3 Europe Melanoma Therapeutics Market Forecasts and Analysis - By Therapy
9.2.4 Europe Melanoma Therapeutics Market Forecasts and Analysis - By Drugs
9.2.5 Europe Melanoma Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Melanoma Therapeutics Market
9.2.5.1.1 Germany Melanoma Therapeutics Market by Therapy
9.2.5.1.2 Germany Melanoma Therapeutics Market by Drugs
9.2.5.2 France Melanoma Therapeutics Market
9.2.5.2.1 France Melanoma Therapeutics Market by Therapy
9.2.5.2.2 France Melanoma Therapeutics Market by Drugs
9.2.5.3 Italy Melanoma Therapeutics Market
9.2.5.3.1 Italy Melanoma Therapeutics Market by Therapy
9.2.5.3.2 Italy Melanoma Therapeutics Market by Drugs
9.2.5.4 Spain Melanoma Therapeutics Market
9.2.5.4.1 Spain Melanoma Therapeutics Market by Therapy
9.2.5.4.2 Spain Melanoma Therapeutics Market by Drugs
9.2.5.5 United Kingdom Melanoma Therapeutics Market
9.2.5.5.1 United Kingdom Melanoma Therapeutics Market by Therapy
9.2.5.5.2 United Kingdom Melanoma Therapeutics Market by Drugs
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Melanoma Therapeutics Market Overview
9.3.2 Asia-Pacific Melanoma Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Melanoma Therapeutics Market Forecasts and Analysis - By Therapy
9.3.4 Asia-Pacific Melanoma Therapeutics Market Forecasts and Analysis - By Drugs
9.3.5 Asia-Pacific Melanoma Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Melanoma Therapeutics Market
9.3.5.1.1 Australia Melanoma Therapeutics Market by Therapy
9.3.5.1.2 Australia Melanoma Therapeutics Market by Drugs
9.3.5.2 China Melanoma Therapeutics Market
9.3.5.2.1 China Melanoma Therapeutics Market by Therapy
9.3.5.2.2 China Melanoma Therapeutics Market by Drugs
9.3.5.3 India Melanoma Therapeutics Market
9.3.5.3.1 India Melanoma Therapeutics Market by Therapy
9.3.5.3.2 India Melanoma Therapeutics Market by Drugs
9.3.5.4 Japan Melanoma Therapeutics Market
9.3.5.4.1 Japan Melanoma Therapeutics Market by Therapy
9.3.5.4.2 Japan Melanoma Therapeutics Market by Drugs
9.3.5.5 South Korea Melanoma Therapeutics Market
9.3.5.5.1 South Korea Melanoma Therapeutics Market by Therapy
9.3.5.5.2 South Korea Melanoma Therapeutics Market by Drugs
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Melanoma Therapeutics Market Overview
9.4.2 Middle East and Africa Melanoma Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Melanoma Therapeutics Market Forecasts and Analysis - By Therapy
9.4.4 Middle East and Africa Melanoma Therapeutics Market Forecasts and Analysis - By Drugs
9.4.5 Middle East and Africa Melanoma Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Melanoma Therapeutics Market
9.4.5.1.1 South Africa Melanoma Therapeutics Market by Therapy
9.4.5.1.2 South Africa Melanoma Therapeutics Market by Drugs
9.4.5.2 Saudi Arabia Melanoma Therapeutics Market
9.4.5.2.1 Saudi Arabia Melanoma Therapeutics Market by Therapy
9.4.5.2.2 Saudi Arabia Melanoma Therapeutics Market by Drugs
9.4.5.3 U.A.E Melanoma Therapeutics Market
9.4.5.3.1 U.A.E Melanoma Therapeutics Market by Therapy
9.4.5.3.2 U.A.E Melanoma Therapeutics Market by Drugs
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Melanoma Therapeutics Market Overview
9.5.2 South and Central America Melanoma Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Melanoma Therapeutics Market Forecasts and Analysis - By Therapy
9.5.4 South and Central America Melanoma Therapeutics Market Forecasts and Analysis - By Drugs
9.5.5 South and Central America Melanoma Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Melanoma Therapeutics Market
9.5.5.1.1 Brazil Melanoma Therapeutics Market by Therapy
9.5.5.1.2 Brazil Melanoma Therapeutics Market by Drugs
9.5.5.2 Argentina Melanoma Therapeutics Market
9.5.5.2.1 Argentina Melanoma Therapeutics Market by Therapy
9.5.5.2.2 Argentina Melanoma Therapeutics Market by Drugs
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL MELANOMA THERAPEUTICS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MELANOMA THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. AB SCIENCES
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. AMGEN, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ASTRAZENECA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. BRISTOL-MYERS SQUIBB COMPANY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. CELGENE CORPORATION
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. DAIICHI SANKYO COMPANY, LIMITED
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMAN-LA ROCHE LTD.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MERCK AND CO., INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVARTIS AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. AB Sciences
2. Amgen, Inc.
3. AstraZeneca
4. Bristol-Myers Squibb Company
5. Celgene Corporation
6. Daiichi Sankyo Company, Limited
7. F. Hoffman-La Roche Ltd.
8. Merck & Co., Inc.
9. Novartis AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For